Nateglinide/Metformin Hydrochloride

那格列奈/盐酸二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNateglinide/Metformin Hydrochloride

Drug Alias NameNateglinide/Metformin二甲双胍+那格列奈那格列奈盐酸二甲双胍Metformin and Nateglinide那格列奈二甲双胍 +[10]

ClassificationSmall molecules

Mechanisms of ActionPotassium channel blockersProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsVoltage-gated potassium channel blockers

TargetsPotassium channelVoltage-gated potassium channelProtein kinase AMP-activated non-catalytic subunit beta 1

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Metformin Hydrochloride Nateglinide

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIldong Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIldong Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A